BACKGROUND: Remodeling of myocardial phospholipids has been reported in various forms of heart failure for decades, but the mechanism and pathophysiological relevance of this phenomenon have remained unclear. We examined the hypothesis that δ-6 desaturase (D6D), the rate-limiting enzyme in long-chain polyunsaturated fatty acid biosynthesis, mediates the signature pattern of fatty acid redistribution observed in myocardial phospholipids after chronic pressure overload and explored plausible links between this process and disease pathogenesis. METHODS AND RESULTS: Compositional analysis of phospholipids from hearts explanted from patients with dilated cardiomyopathy revealed elevated polyunsaturated fatty acid product/precursor ratios reflective of D6D hyperactivity, manifesting primarily as lower levels of linoleic acid with reciprocally higher levels of arachidonic and docosahexaenoic acids. This pattern of remodeling was attenuated in failing hearts chronically unloaded with a left ventricular assist device. Chronic inhibition of D6D in vivo reversed similar patterns of myocardial polyunsaturated fatty acid redistribution in rat models of pressure overload and hypertensive heart disease and significantly attenuated cardiac hypertrophy, fibrosis, and contractile dysfunction in both models. D6D inhibition also attenuated myocardial elevations in pathogenic eicosanoid species, lipid peroxidation, and extracellular receptor kinase 1/2 activation; normalized cardiolipin composition in mitochondria; reduced circulating levels of inflammatory cytokines; and elicited model-specific effects on cardiac mitochondrial respiratory efficiency, nuclear factor κ B activation, and caspase activities. CONCLUSIONS: These studies demonstrate a pivotal role of essential fatty acid metabolism in myocardial phospholipid remodeling induced by hemodynamic stress and reveal novel links between this phenomenon and the propagation of multiple pathogenic systems involved in maladaptive cardiac remodeling and contractile dysfunction [corrected].
BACKGROUND: Remodeling of myocardial phospholipids has been reported in various forms of heart failure for decades, but the mechanism and pathophysiological relevance of this phenomenon have remained unclear. We examined the hypothesis that δ-6 desaturase (D6D), the rate-limiting enzyme in long-chain polyunsaturated fatty acid biosynthesis, mediates the signature pattern of fatty acid redistribution observed in myocardial phospholipids after chronic pressure overload and explored plausible links between this process and disease pathogenesis. METHODS AND RESULTS: Compositional analysis of phospholipids from hearts explanted from patients with dilated cardiomyopathy revealed elevated polyunsaturated fatty acid product/precursor ratios reflective of D6Dhyperactivity, manifesting primarily as lower levels of linoleic acid with reciprocally higher levels of arachidonic and docosahexaenoic acids. This pattern of remodeling was attenuated in failing hearts chronically unloaded with a left ventricular assist device. Chronic inhibition of D6D in vivo reversed similar patterns of myocardial polyunsaturated fatty acid redistribution in rat models of pressure overload and hypertensive heart disease and significantly attenuated cardiac hypertrophy, fibrosis, and contractile dysfunction in both models. D6D inhibition also attenuated myocardial elevations in pathogenic eicosanoid species, lipid peroxidation, and extracellular receptor kinase 1/2 activation; normalized cardiolipin composition in mitochondria; reduced circulating levels of inflammatory cytokines; and elicited model-specific effects on cardiac mitochondrial respiratory efficiency, nuclear factor κ B activation, and caspase activities. CONCLUSIONS: These studies demonstrate a pivotal role of essential fatty acid metabolism in myocardial phospholipid remodeling induced by hemodynamic stress and reveal novel links between this phenomenon and the propagation of multiple pathogenic systems involved in maladaptive cardiac remodeling and contractile dysfunction [corrected].
Authors: Jacquelyn M Walejko; Andrew Antolic; Jeremy P Koelmel; Timothy J Garrett; Arthur S Edison; Maureen Keller-Wood Journal: Am J Physiol Endocrinol Metab Date: 2019-01-08 Impact factor: 4.310
Authors: E Madison Sullivan; Amy Fix; Miranda J Crouch; Genevieve C Sparagna; Tonya N Zeczycki; David A Brown; Saame Raza Shaikh Journal: J Nutr Biochem Date: 2017-04-12 Impact factor: 6.048
Authors: Laura K Cole; Prasoon Agarwal; Christine A Doucette; Mario Fonseca; Bo Xiang; Genevieve C Sparagna; Nivedita Seshadri; Marilyne Vandel; Vernon W Dolinsky; Grant M Hatch Journal: Endocrinology Date: 2021-07-01 Impact factor: 4.736
Authors: Tyler Wallace; Derek Schaeuble; Sebastian A Pace; Morgan K Schackmuth; Shane T Hentges; Adam J Chicco; Brent Myers Journal: Psychoneuroendocrinology Date: 2021-04-21 Impact factor: 4.693
Authors: Janek Salatzki; Anna Foryst-Ludwig; Kajetan Bentele; Annelie Blumrich; Elia Smeir; Zsofia Ban; Sarah Brix; Jana Grune; Niklas Beyhoff; Robert Klopfleisch; Sebastian Dunst; Michal A Surma; Christian Klose; Michael Rothe; Frank R Heinzel; Alexander Krannich; Erin E Kershaw; Dieter Beule; P Christian Schulze; Nikolaus Marx; Ulrich Kintscher Journal: PLoS Genet Date: 2018-01-10 Impact factor: 5.917
Authors: Brenda Bakker; Gert B Eijkel; Ron M A Heeren; Marcel Karperien; Janine N Post; Berta Cillero-Pastor Journal: Anal Chem Date: 2017-08-14 Impact factor: 6.986